Drug intelligence / Profile preview

RBS-009

Development stage: Preclinical
Lead developer: RophiBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RBS-009 is a biosimilar monoclonal antibody candidate developed by RophiBio that targets programmed death-ligand 1 (PD-L1). It is designed as a biosimilar to the reference product atezolizumab (Tecentriq). The mechanism of action involves binding to PD-L1 on the surface of tumor cells and tumor-infiltrating immune cells, thereby blocking its interaction with the PD-1 and B7.1 (CD80) receptors. This blockade prevents the inhibitory signaling that normally suppresses T-cell activation, effectively restoring the immune system's ability to recognize and eliminate cancer cells. RBS-009 is currently in the preclinical stage of development for various oncology indications.

Other names: Atezolizumab biosimilar

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on RBS-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBS-009.

Explore the full profile